Immune cells tailored to attack lung cancer show promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with stage III, IV or relapsed lung cancer confirmed by histology and biopsy. 2. Age: ≥ 18 years and ≤ 80 years. 3. 4 weeks at least since last chemotherapy or radiotherapy and 2 weeks at least since last systemic steroid hormone and other immunosuppressive therapy. 4. Side Effects of Chemotherapy have subsided. 5. Cancer specific antigens are identified and shown to express at high levels (\>2+) in malignant tissues by immuno-histochemical staining or flow cytometry. 6. Karnofsky/Lansky ≥ 50%. 7. Expected survival ≥ 6 weeks. Initial hematopoietic conditions with * neutrophils (ANC) ≥ 1×10\^6/L; * platelet (PLT) ≥ 1×10\^8/L. Proper renal and hepatic functions (ULN denotes "upper limit of normal range") with * serum creatinine ≤ 2×ULN; * serum bilirubin ≤ 3×ULN; * AST/ALT ≤ 5×ULN. 10\. Oxygen saturation ≥ 90%. 11. Written, informed consent obtained prior to any study-specific procedures. Exclusion Criteria: 1. Airway obstruction caused by tumor. 2. History of epilepsy or other central nervous system diseases. 3. Patients who require systemic corticosteroid or other immunosuppressive therapy. 4. History of prolonged or serious heart disease during QT. 5. history of serious cyclophosphamide toxicity. 6. Current or recent treatment (within the 28-day period prior to Day 0) with another investigational drug or previous participation in any immune cell therapy study. Inadequate liver and renal function with * serum creatinine \> 2.5 mg/dl; * serum (total) bilirubin \> 2.0 mg/dl; * AST \& ALT \> 3 x ULN. 8\. Pregnant or lactating females. 9. Serious active infection during screening. 10. Active HIV, Hepatitis B virus (HBV), Hepatitis C virus (HCV) infection or uncontrolled infection. 11\. Patients, in the opinion of investigators, may not be eligible or not able to comply with the study.